Is Oncolytics Biotech Stock a Good Investment?
Oncolytics Biotech Investment Advice | ONCY |
- Examine Oncolytics Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Oncolytics Biotech's leadership team and their track record. Good management can help Oncolytics Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Oncolytics Biotech's business and its evolving consumer preferences.
- Compare Oncolytics Biotech's performance and market position to its competitors. Analyze how Oncolytics Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Oncolytics Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Oncolytics Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Oncolytics Biotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Oncolytics Biotech is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Oncolytics Biotech Stock
Researching Oncolytics Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.26. Oncolytics Biotech last dividend was issued on the 25th of May 2018. The entity had 10:95 split on the 25th of May 2018.
To determine if Oncolytics Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oncolytics Biotech's research are outlined below:
| Oncolytics Biotech had very high historical volatility over the last 90 days | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Oncolytics Biotech Inc. Q3 2024 Earnings Call Transcript |
Oncolytics Biotech Quarterly Liabilities And Stockholders Equity |
|
Oncolytics Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oncolytics Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oncolytics Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Oncolytics Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Oncolytics Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2022-08-11 | 2022-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2020-11-11 | 2020-09-30 | -0.14 | -0.16 | -0.02 | 14 | ||
2024-11-04 | 2024-09-30 | -0.07 | -0.0908 | -0.0208 | 29 | ||
2023-05-05 | 2023-03-31 | -0.13 | -0.1 | 0.03 | 23 | ||
2022-11-07 | 2022-09-30 | -0.11 | -0.08 | 0.03 | 27 | ||
2022-05-05 | 2022-03-31 | -0.15 | -0.12 | 0.03 | 20 | ||
2020-08-04 | 2020-06-30 | -0.14 | -0.17 | -0.03 | 21 |
Know Oncolytics Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oncolytics Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncolytics Biotech backward and forwards among themselves. Oncolytics Biotech's institutional investor refers to the entity that pools money to purchase Oncolytics Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bmo Capital Markets Corp. | 2024-06-30 | 37.4 K | Virtu Financial Llc | 2024-06-30 | 27.4 K | Brave Asset Management Inc | 2024-09-30 | 25 K | Newman Dignan & Sheerar Inc | 2024-09-30 | 22 K | Financial Advisory Corp /ut/ /adv | 2024-09-30 | 20.6 K | Lpl Financial Corp | 2024-09-30 | 20.5 K | Head & Associates, Llc | 2024-09-30 | 17.4 K | C2p Capital Advisory Group Llc Dba Prosperity Capital Advisors | 2024-09-30 | 15 K | Ausdal Financial Partners Inc | 2024-09-30 | 14 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 277 K | Seeds Investor Llc | 2024-09-30 | 189.9 K |
Oncolytics Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 71.68 M.Market Cap |
|
Oncolytics Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.01) | (0.96) |
Determining Oncolytics Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Oncolytics Biotech is a good buy. For example, gross profit margin measures Oncolytics Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oncolytics Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Oncolytics Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncolytics Biotech. Check Oncolytics Biotech's Beneish M Score to see the likelihood of Oncolytics Biotech's management manipulating its earnings.
Evaluate Oncolytics Biotech's management efficiency
Oncolytics Biotech has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3822) %, meaning that it created substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.75 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Oncolytics Biotech's Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 32 M in 2024, whereas Total Assets are likely to drop slightly above 30.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.41 | 0.39 | |
| Tangible Book Value Per Share | 0.41 | 0.39 | |
| Enterprise Value Over EBITDA | (2.48) | (2.61) | |
| Price Book Value Ratio | 4.29 | 4.50 | |
| Enterprise Value Multiple | (2.48) | (2.61) | |
| Price Fair Value | 4.29 | 4.50 | |
| Enterprise Value | 83.7 M | 118 M |
Oncolytics Biotech showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.506 |
Basic technical analysis of Oncolytics Stock
As of the 28th of November, Oncolytics Biotech holds the Semi Deviation of 3.53, coefficient of variation of 7489.51, and Risk Adjusted Performance of 0.0188. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncolytics Biotech, as well as the relationship between them.Oncolytics Biotech's Outstanding Corporate Bonds
Oncolytics Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncolytics Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncolytics bonds can be classified according to their maturity, which is the date when Oncolytics Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Oncolytics Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Oncolytics Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0188 | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 3.45 | |||
| Semi Deviation | 3.53 | |||
| Downside Deviation | 3.89 | |||
| Coefficient Of Variation | 7489.51 | |||
| Standard Deviation | 5.47 | |||
| Variance | 29.96 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.1365 | |||
| Total Risk Alpha | (0.76) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | (0.1) | |||
| Maximum Drawdown | 36.56 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 7.83 | |||
| Downside Variance | 15.14 | |||
| Semi Variance | 12.48 | |||
| Expected Short fall | (4.81) | |||
| Skewness | 2.43 | |||
| Kurtosis | 9.94 |
| Risk Adjusted Performance | 0.0188 | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 3.45 | |||
| Semi Deviation | 3.53 | |||
| Downside Deviation | 3.89 | |||
| Coefficient Of Variation | 7489.51 | |||
| Standard Deviation | 5.47 | |||
| Variance | 29.96 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.1365 | |||
| Total Risk Alpha | (0.76) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | (0.1) | |||
| Maximum Drawdown | 36.56 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 7.83 | |||
| Downside Variance | 15.14 | |||
| Semi Variance | 12.48 | |||
| Expected Short fall | (4.81) | |||
| Skewness | 2.43 | |||
| Kurtosis | 9.94 |
Consider Oncolytics Biotech's intraday indicators
Oncolytics Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oncolytics Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Oncolytics Biotech time-series forecasting models is one of many Oncolytics Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncolytics Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Oncolytics Stock media impact
Far too much social signal, news, headlines, and media speculation about Oncolytics Biotech that are available to investors today. That information is available publicly through Oncolytics media outlets and privately through word of mouth or via Oncolytics internal channels. However, regardless of the origin, that massive amount of Oncolytics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Oncolytics Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Oncolytics Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Oncolytics Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Oncolytics Biotech alpha.
Oncolytics Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Oncolytics Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Oncolytics Biotech Corporate Management
| Amy Levin | Vice Operations | Profile | |
| FCA FCA | Consultant | Profile | |
| Jon Patton | Director Communication | Profile | |
| FACP FACP | Consultant | Profile | |
| Wayne MBA | Interim Board | Profile | |
| Andrew Guttadauro | Global Inc | Profile |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.